Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate * Recurrent prostate cancer following primary therapy as defined by: * Post-radical prostatectomy: Any PSA \>= 0.4 ng/ml * Post-primary radiotherapy: PSA \>= 2 ng/ml above a post-radiotherapy nadir * Post-primary androgen-deprivation therapy: A confirmed rise of PSA \>= 2 ng/ml above a post-therapy nadir * For patients with non-castrate levels of circulating androgen levels (testosterone \>= 50 g/dl) * PSA levels should be increasing on at least two occasions \>= 1 week apart * Patients should not be considered candidates for radiation therapy * For patients with castrate levels of circulating androgen levels (testosterone \< 50 ng/dl): * PSA levels must be \>= 0.4 ng/ml (if history of radical prostatectomy) or \>= 2 ng/ml (if history of non-surgical primary treatment) and found to be increasing on at least two occasions \>= 1 week apart * At least 4 weeks must have elapsed since any changes to hormonal therapy, including at least 4 weeks since flutamide and at least 6 weeks since bicalutamide, nilutamide, or enzalutamide * No evidence of metastatic cancer on imaging including a bone scan and computed tomography (CT) scan of chest/abdomen/pelvis * Able to understand and adhere to dietary and medication restrictions as recommended for the safe use of phenelzine * Men with child bearing potential are required to use an effective means of contraception * Leukocytes \>= 3,000/mcL * Absol…